Transmedics Group Stock Price, News & Analysis

TransMedics Group (Nasdaq: TMDX), a leader in organ transplant technology, will present at the Cowen 41st Annual Healthcare Conference on March 3, 2021, at 3:20 p.m. EST. The virtual presentation aims to showcase their advancements in organ preservation and assessment, addressing the critical need for improved organ availability for transplantation. A live and archived webcast will be accessible via the TransMedics Investors website. Founded in Andover, Mass., TransMedics focuses on enhancing the viability of donor organs for patients with end-stage heart, lung, and liver failure.

TransMedics Group, Inc. (Nasdaq: TMDX) will announce its fourth quarter and full year 2020 financial results on March 2, 2021, after market close. A conference call will follow at 4:30 p.m. ET. The company specializes in organ transplant therapy and aims to improve organ quality and viability assessment. Investors can access the conference by calling (833) 378-1026 domestically or (236) 712-2500 internationally, using Conference ID: 3751905. A webcast will be available on their Investor website.

TransMedics Group (Nasdaq: TMDX) announced its management will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2020, at 5:20 p.m. EST. The company specializes in transforming organ transplant therapy through portable extracorporeal warm perfusion technology.

The presentation will be accessible live and in archive via the Investors section of their website.

TransMedics Group announced the appointment of Merilee Raines to its Board of Directors and the Audit Committee, effective January 1, 2021. She will serve as Chair of the Audit Committee starting June 1, 2021. With over 30 years of executive experience, including a significant tenure as CFO at IDEXX Laboratories, Raines is expected to contribute valuable insights as TransMedics aims to enhance its position in the organ transplantation market. CEO Waleed Hassanein expressed confidence in her role for the company's future growth.

TransMedics Group, Inc. (TMDX) reported third-quarter 2020 net revenue of $7.1 million, a 2% decrease from Q3 2019. The decline was primarily due to the ongoing effects of the COVID-19 pandemic. Gross margin improved to 71% from 59% year-over-year, while operating expenses decreased to $9.6 million from $11.5 million. The net loss for the quarter was $5.1 million, a reduction from $8.3 million in the same period last year. Cash reserves stood at $132.7 million as of September 30, 2020.

TransMedics Group, Inc. (NASDAQ: TMDX) announced its participation in two virtual investor conferences. The management team will attend the Oppenheimer Fall MedTech Summit on November 12, 2020, and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020. These events will consist of 1x1 meetings only, with no webcasts available. TransMedics is a leader in portable extracorporeal warm perfusion for organ transplantation, focusing on enhancing organ quality and viability for patients with end-stage organ failure.

TransMedics Group, Inc. (TMDX) will release its third-quarter financial results on November 4, 2020, after market close. Following this, a conference call will be held at 4:30 p.m. ET. Investors can access the call by dialing (833) 378-1026 domestically or (236) 712-2500 internationally, using Conference ID: 1716957. TransMedics is a leader in organ transplant technologies, focusing on enhancing organ quality and increasing the utilization of donor organs for patients with end-stage organ failure.

TransMedics Group announced that the FDA has postponed the Advisory Committee meeting originally set for October 7, 2020, to review its OCS Heart premarket approval application. This delay allows the FDA to evaluate additional data from the OCS Heart EXPAND trial and its Continued Access Protocol. Despite the setback, TransMedics remains confident in the trial results supporting the OCS Heart’s approval to aid heart transplant patients in the U.S.

TransMedics Group, Inc. (Nasdaq: TMDX) announced the FDA's postponement of the Advisory Committee meeting regarding its OCS Heart premarket approval application, originally set for October 7, 2020. The delay allows the FDA to review additional data from the OCS Heart EXPAND trial. CEO Waleed Hassanein expressed disappointment but remains confident that the results will support FDA approval. The company specializes in portable organ preservation technologies aimed at enhancing organ transplantation outcomes.